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signiﬁcantly reduced at 12 months as compared to the baseline. The KOOS
for other knee symptoms (p=0.096), diﬃculty during activities of daily
living (p=0.092), and sports and recreation (p=0.061) were signiﬁcantly
reduced at 4 months as compared to the baseline. Radiographic parameters
were not statistically different between baseline and 12 month follow-up
visits.
Conclusions: We observed signiﬁcant knee pain reduction and functional
improvement with Unloader® One brace therapy for varus knee OA at 4
and 12 months, based on several VAS and KOOS subcategories. In addition,
no signiﬁcant radiographic changes in our study, albeit limited sample size,
may also be indicative of favorable outcome. However, considering that
signiﬁcant radiographic changes have been observed as early as 18 months
in past studies, longer-term data from additional subjects will be helpful
to derive deﬁnitive conclusions regarding the effects of Unloader® brace
therapy on progression of knee OA.
Acknowledgements: Össur Americas and New Balance - for providing
custom braces and shoes respectively
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THE COST-EFFECTIVENESS OF EXERCISE THERAPY ADDED TO GENERAL
PRACTITIONERS’ CARE FOR HIP OSTEOARTHRITIS COMPARED TO
GENERAL PRACTITIONERS’ CARE ALONE - STUDY DESIGN OF AN RCT
P.P. van Es1, P.A. Luijsterburg1, M.A. Koopmanschap1, J. Dekker2,
J.A. Verhaar1, B.W. Koes1, S.M. Bierma-Zeinstra1
1Erasmus MC Univ. Med. Ctr., Rotterdam, Netherlands; 2VU Univ. Med. Ctr.
Amsterdam, Amsterdam, Netherlands
Purpose: Osteoarthritis is associated with high (healthcare) costs because of
its high prevalence and its clinical implications. However, studies evaluating
costs are lacking. This randomised controlled trial investigates the cost-
effectiveness of exercise therapy added to general practitioners’ care for pa-
tients with hip osteoarthritis compared to general practitioners’ care alone.
Methods: Patients aged 45 or older with hip osteoarthritis, who consulted
the general practitioner during the past year regarding hip complaints, will
be included in this trial. Patients are randomly assigned to either exercise
therapy added to general practitioners’ care or to general practitioners’
care alone. Exercise therapy consists of maximally 12 treatment sessions
during three months, supervised by a physiotherapist. These are followed
by three additional treatment sessions in the 5th, 7th and 9th month after
the ﬁrst treatment session. General practitioners’ care consists of usual care
for hip osteoarthritis, such as prescribing pain medication, referring for
radiographic examination or referring to secondary care. Primary outcomes
are hip pain and hip function (Hip disability Osteoarthritis Outcome Score),
direct costs and productivity costs (PRODISQ questionnaire). These param-
eters are measured at baseline and at 6 weeks, 3, 6, 9, and 12 months
follow-up.
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LOW-INTENSITY ULTRASOUND ALLEVIATES OSTEOARTHRITIS AND
SYNOVIAL EDEMA IN THE KNEE JOINTS IN ANTERIOR CUCIATE LIGAMENT
-MENISCUS LIGAMENT TRANSECTION RABBIT MODEL
A. Seo1, S. Park1, K. Kim1, B. Choi1, B.-H. Min2, H. Lee2
1Inha Univ school of medicine, Incheon, Korea, Republic of; 2Dept. of
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Purpose: LIUS has been shown to relieve pain and progression of os-
teoarthritis (OA) in a rabbit model, when co-treated with hyaluronan. This
study further investigated the LIUS effect on the repair of OA and reduction
of synovial edema in the rabbit model of OA
Methods: The anterior cruciate ligaments (ACLs) of adult male New Zealand
white rabbits were transected to induce OA. The left knee joint served as
a sham control. LIUS was treated at 1 MHz, 100 mW/cm2 on the right
knee every for 10 min until the end of analysis. The left knee joint was
exposed to sham LIUS as a control. The rabbits were sacriﬁced at 2 and 4
weeks postoperatively. Histological observation was performed to evaluate
the composition and distribution of chondrocytes and extracellular matrix
(ECM) by hematoxylin/eosin stain, Safranin-O stain and immunostain for
collagen type II, collagen type X and MMP9. The amount of synovial ﬂuid
was also measured.
Results: In the histological observation, LIUS reduced progression of
OA-phenotypes such as loss of cells, decrease in the levels of sulfated
glycosamionoglycans (GAGs) and type II collagen, and induced expression
of type X collagens and matrix metalloproteinase-3 (MMP-13). LIUS also
reduced the amount of synovial ﬂuid and release of collagen type II and
GAGs fragments into synovial cavity. With regard to the cellular target of
LIUS, aquaporins (AQP1) on the cell surface appeared to be activated by
LIUS and mediate at least to some part therapeutic effect of LIUS.
Conclusions: This study showed that LIUS alleviated the progression of OA
probably via inhibiting abnormal increase of synovial ﬂuid, and could be
utilized to treat OA or related disorders.
Therapy – Pharmacologic
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EVIDENCE-BASED TAILORED CONSERVATIVE TREATMENT OF KNEE AND
HIP OA: BETWEEN KNOWING AND DOING
G. Snijders1 , A. den Broeder1, P. van Riel2, V. Straten1, H. de Man1, F. van
den Hoogen1, E. van den Ende1
1Sint Maartenskliniek, Nijmegen, Netherlands; 2Radboud Univ. Nijmegen Med.
Ctr., Nijmegen, Netherlands
Purpose: Insuﬃcient data is available on the use and eﬃcacy of combined
conservative interventions recommended in several treatment guidelines
for knee and hip osteoarthritis (OA). The aims of this study were (1) to
describe the use of conservative treatment modalities for knee and/or hip
OA in daily practice and (2) to estimate the effect of an evidence- based
12-week tailored multimodal conservative treatment protocol for patients
with knee and/or hip OA.
Methods: After obtaining data on previous OA related interventions, multi-
modal treatment was offered to patients with knee and/or hip OA referred
to secondary care. Treatment with analgesics was tailored using a numeric
rating scale (NRS) for pain aiming for NRS ≤ 4. Visits were planned at week
0 and 12 at the out-patient clinic and at week 4 and 8 by telephone. When
NRS pain remained higher than 4, treatment options outlined in the next
step of the stepped care model were offered.
The ﬁrst step of the treatment protocol consisted of education, life style
advise concerning physical activity and weight loss in patients with a
body mass index (BMI) of 28 or higher, referral for physical therapy and
treatment with paracetamol in a ﬁxed dose of three times a day 1000 mg
(in case of no recent use for knee and/or hip complaints). In the second
step, if necessary, and no earlier than after 4 weeks a non-steroidal anti-
inﬂammatory drug (NSAID) was added and eventually changed (step three)
four weeks thereafter. Step four includes the substitution of the NSAID
for tramadol. Primary outcome measure was the proportion of patients
after 12 weeks fulﬁlling OMERACT-OARSI responder criteria. Predictors for
response were identiﬁed using a multivariate logistic regression prediction
model.
Results: Data after 12 weeks were available from 183 out of 231 patients.
There were no signiﬁcant differences between patients with and without
suﬃcient 12-week follow-up data. Baseline characteristics are depicted in
Table 1. The large majority of patients had not been exposed to adequate
conservative treatment modalities for knee and/or hip OA in the past (81%).
Table 1. Baseline characteristics of patients (n=183)
Women, n (%) 128 (70)
Age (years), mean (SD) 56 (10)
BMI, median (p25-75) 29 (25-32)
Knee OA, number (%) 153 (84)
K&L-score ≥ 2, number (%) 109 (48)
Past treatment, number (%)
Key elements of guidelines utilized1 35 (19)
Paracetamol in adequate dose2 66 (36)
One or more NSAID 149 (81)
Opioids3 38 (21)
Physical therapy 118 (64)
Past surgical treatments for knee OA, number (%)
One or more arthroscopies4 86/153 (56)
Open procedures5 26/153 (17)
Past surgical treatments for hip OA, number (%) 4/30 (13)
1Deﬁned as at least: paracetamol ≥ two times a day 1000 mg, at least one NSAID and
physical therapy for knee and/or hip OA; 2Adequate dose: 2-4 times 1000mg/day dur-
ing at least 14 consecutive days; 3Including tramadol; 4Including partial meniscectomy;
5Including joint prosthesis; 6e.g. damage to ligaments. BMI, body mass index; OA, os-
teoarthritis; K&L-score, Kellgren-Lawrence Grading Scale; paracetamol, acetaminophen;
NSAID, non-steroidal anti-inﬂammatory drug.
S250 Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256
Table 2. Primary and secondary outcomes
Baseline Week 12 Change 95% CI
Responder (%)1 47 40 to 54
NRS pain (0-10) (SD) 6.7 (1) 5.3 (2) 1.4 (2) -1 to -2
NRS pain (0-10) (SD) 6.7 (1) 5.3 (2) 1.4 (2) -1 to -2
NRS PGA (0-10) (SD) 6.9 (2) 5.6 (2) 1.3 (2) -0.9 to -2
WOMAC-scores, mean (SD)2
pain 57 (19) 52 (23) -5.1 (19) -2 to -8
stiffness 62 (20) 58 (23) -3.8 (23) 0 to -8
function 58 (19) 52 (23) -5.6 (19) -3 to -8
1According to OMERACT-OARSI criteria; 2Scores are normalized (0-100; 0 = no symp-
toms). NRS, numeric rating scale;WOMAC-score,Western Ontario McMaster Universities
score; BMI, body mass index.
Results after 12 weeks are depicted in Table 2. OMERACT-OARSI responder
criteria were fulﬁlled in 47%; 39% reached NRS pain ≤4. In the univariate
analysis, NRS pain at baseline and low number of NSAIDs used for OA were
signiﬁcantly associated with an OMERACT-OARSI response, with only the
latter remaining as independent predictor for OMERACT-OARSI response
after 12 weeks in the multivariate analyses (OR 0.8, p = 0.03). No other
predictors were identiﬁed.
Conclusions: Basic ﬁrst-line recommended conservative treatment options
have not been adequately utilized prior to referral to secondary care in the
large majority of patients, but implementation is feasible and successful
in 47%. Furthermore, response was associated with (lack of) previous
conservative treatment.
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REASSESSING THE ROLE OF ACETAMINOPHEN IN OSTEOARTHRITIS:
SYSTEMATIC REVIEW AND META-ANALYSIS
R.R. Bannuru1, U.R. Dasi2, T.E. McAlindon1
1Tufts Med. Ctr., Boston, MA; 2Nagarjuna Univ., Vijayawada, India
Purpose: Acetaminophen has been for decades recommended as a ﬁrst
line analgesic for osteoarthritis (OA) by consensus guidelines. However,
a recent update of the evidence led OARSI investigators to infer that
evidence for its eﬃcacy has diminished in strength. Furthermore, concerns
have also emerged in respect of its safety. We aimed to reassess the role
of acetaminophen, including the extended release formulation, in OA by
systematic review and latest evidence synthesis of studies reporting data
on its eﬃcacy and safety.
Methods: We searched Medline, EMBASE, CINAHL, BIOSIS, Google Scholar,
ISI Web of Science and Cochrane database from inception to April 2010.
We also hand searched review articles, manuscripts and supplements
from medical journals and contacted authors for unpublished data. We
included all human randomized clinical trials comparing acetaminophen
with placebo for OA. Two reviewers (RB, UD) independently performed
data extraction and assessed the quality of each trial. We computed effect
sizes for pain, function and stiffness (change from baseline) for each study
using Hedges’ g statistic corrected for small sample sizes. Effect sizes were
pooled using DerSimonian and Laird random effects model. Heterogeneity
was estimated with the help of I2 statistic. Sub group analyses were
undertaken for pain to determine whether the quality of trials inﬂuences
the results. Relative risk was calculated for any adverse event, GI events
and withdrawals due to adverse events.
Results: The 10 eligible trials included 3004 participants (acetaminophen
- 1515; placebo - 1489) with an age range of 56 to 70 years. They were
published between 1983 and 2007. Eight trials used immediate release
acetaminophen and two trials used extended release acetaminophen as an
active agent. The sample sizes varied between 25 and 779 with a mean of
300; 3 trials had a sample size less than 100. Trial duration ranged from 1 to
24 weeks. Allocation concealment was adequate in 4 trials. Intent-to-treat
analysis results were reported in 8 trials. Dropout rates ranged from 7 to
30% with 4 trials reporting >20%. Seven were industry sponsored trials and
one was sponsored by NIH.
For pain, we found a pooled effect size (ES) of 0.18 (95%CI 0.11, 0.25) favor-
ing acetaminophen with a heterogeneity score (I2) of 0% (Table 1A, Figure
1). For function, ES was 0.16 (95%CI 0.01, 0.31) favoring acetaminophen.
For stiffness, ES was 0.20 (95%CI 0.09, 0.32) favoring acetaminophen. The
sub group analyses showed no difference in eﬃcacy between different
formulations (Table 1B). However, safety analysis showed increase risk
in GI adverse events, more signiﬁcantly among the trials reporting liver
function tests (RR = 4.13 (2.11, 8.07) (Table 1C).
Table 1. Meta-analysis results
A. Pooled effect sizes (95% CI)
Trials N ES (95% CI) I2 (%)
Pain 9 2979 0.18 (0.11, 0.25) 0
Function 5 1915 0.16 (0.01, 0.31) 59
Stiffness 4 1218 0.20 (0.09, 0.32) 5
B. Sensitivity analyses for pain
Trials N ES (95% CI) I2 (%)
Immediate Release Acetaminophen 7 2112 0.17 (0.08, 0.25) 0
Extended Release Acetaminophen 2 867 0.21 (0.08, 0.35) 0
Intent-to-treat Analysis 8 2919 0.17 (0.10, 0.25) 0
Allocation Concealment 4 1247 0.25 (0.14, 0.36) 0
N > 100 7 2862 0.17 (0.10, 0.25) 0
C: Adverse events (Relative Risk)
Trials N RR (95% CI) I2 (%)
Any adverse events 9 2981 1.02 (0.93, 1.11) 0
Withdrawals due to adverse events 8 2683 1.21 (0.89, 1.65) 0
Any gastrointestinal adverse events 8 3373 1.40 (1.03, 1.89) 47
Increased hepatic enzyme levels 3 1079 4.13 (2.11, 8.07) 0
Figure 1. Forest plot.
Conclusions: This meta-analysis conﬁrms eﬃcacy of acetaminophen over
placebo, albeit at a low level barely reaching the minimal clinical thresh-
old. We also detected increase risk in GI adverse events with signiﬁcant
increases in liver enzymes. Therefore, acetaminophen as a short-term
analgesic in OA may still have utility, but with a questionable safety proﬁle.
Future randomized trials should include a longer duration of follow-up to
fully evaluate safety.
559
EVALUATION OF THE STRUCTURE-MODIFYING EFFECT OF
AVOCADO-SOYBEAN UNSAPONIFIABLES (ASU) IN HIP OSTEOARTHRITIS
(OA): RESULTS OF THE ERADIAS STUDY, A 3-YEAR PROSPECTIVE,
RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL
E. Maheu1, C. Cadet2, M. Marty3, D. Moyse4, I. Kerloch5, P. Coste5,
M. Dougados6, B. Mazières7, T.D. Spector8, E. Vignon9, J.-M. Grouin10,
M. Lequesne11
1St Antoine Hosp.-Rheumatology Dept., Paris, France; 2Rheumatology oﬃce,
Paris, France; 3Rheumatology, Henri Mondor Hosp., Creteil, France; 4Statistics,
DM Consultant, Tours, France; 5Med. dept, ExpanSci. Labs, Courbevoie, France;
6Rheumatology B, Cochin Hosp- AP-HP, Paris, France; 7Rheumatology, CHU
Larrey, Toulouse, France; 8Twin Res., King’s Coll. Hosp., London, United
Kingdom; 9Rheumatology, Lyon Sud Univ. hosp, Lyon, France; 10Biostatistics,
Rouen Univ., Rouen, France; 11Rheumatology, Léopold Bellan hosp., Paris,
France
Purpose: To assess the long-term ability of ASU to slow radiographic
progression in symptomatic hip OA
